Riverside

FDA Expands Eligibility for Pfizer COVID-19 Vaccine Booster Dose for Children 5 through 11 Years – Riverside, California

Riverside, California 2022-05-17 19:00:00 –

CORPUS CHRISTI, TX-Today, the U.S. Food and Drug Administration (FDA) amends the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to provide a single booster dose to individuals for 5-11 years. Allowed. At least 5 months of age after completion of the primary series with the Pfizer-BioNTech COVID-19 vaccine.

On January 3, the FDA approved the use of a single booster immunization of the Pfizer-BioNTech COVID-19 vaccine. Individuals aged 12 to 15 After completion of primary vaccination with Pfizer-BioNTech COVID-19 vaccine.

Today’s behavior is the FDA analysis of immune response data in a subset of children from an ongoing randomized placebo-controlled trial that supported the October 2021 approval of the Pfizer-BioNTech COVID-19 vaccine primary series in this age group. It is based on.

The antibody response was evaluated in 67 study participants who received booster immunization 7-9 months after completing the double-dose primary series of Pfizer-BioNTech COVID-19 vaccine. The antibody level against SARS-CoV-2 virus 1 month after the booster administration was increased compared to before the booster administration.

Boosters have been approved by the FDA, but CDC and DSHS approvals between the ages of 5 and 11 are still pending. The meeting for CDC approval is set for Thursday, May 19th.

Once all approvals have been finalized, the public health district will notify the residents.

FDA Expands Eligibility for Pfizer COVID-19 Vaccine Booster Dose for Children 5 through 11 Years Source link FDA Expands Eligibility for Pfizer COVID-19 Vaccine Booster Dose for Children 5 through 11 Years

Back to top button